Journal Logo

THE NATURAL ANTICOAGULANTS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

PB2232

Efremova, E.1; Korsakova, N.2; Matvienko, O.2; Fominykh, M.1; Silina, N.2; Golovina, O.2; Papayan, L.2; Martynkevich, I.3; Samorodova, A.3; Polushkina, L.3; Voloshin, S.1; Shuvaev, V.1

doi: 10.1097/01.HS9.0000567404.64167.17
Publication Only: Myeloproliferative neoplasms - Clinical
Free

1Clinical Department

2Laboratory of Coagulation

3Laboratory of molecular genetics, Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation

Back to Top | Article Outline

Background:

Myeloproliferative neoplasms (MPNs) are characterized by an increased frequency of thrombotic complications. Patients with MPNs show little or no abnormalities in traditional coagulation tests. Chronic inflammation associated with pathological secretion of several inflammatory cytokines leads to activation of endothelial cells and imbalance between coagulation and anticoagulation systems.

Back to Top | Article Outline

Aims:

To estimate the natural anticoagulants activity and activated protein C resistance in MPNs patients.

Back to Top | Article Outline

Methods:

The study included 99 MPNs patients (aged 25 - 86 years, median = 55) and 43 healthy controls (aged 30-73 years, median = 46). There were 65 female and 34 male in the study group. 75 (76%) patients were JAK2V617F positive, 24 (24%) were JAK2V617F negative. Antithrombin (AT), protein C (PC) activities and free protein S level (PS) estimation was performed by standard techniques. Thrombin generation was assessed by calibrated automated thrombinography (CAT) according to Hemker et al. Measurement was conducted in platelet poor plasma with or without thrombomodulin (TM). Such parameters as endogenous thrombin potential (ETP, nM*min) and peak thrombin (Peak, nM) were evaluated. ETP and Peak sensitivity for TM were calculated as percent of these parameters decrease after TM adding to assay (S ETP, % and S Peak, % respectively). STATISTICA 6.0 package was used for data analysis. Parameter results were presented as median (Me) with 95% confidence intervals (CI), p<0.05 was considered statistically significant.

Back to Top | Article Outline

Results:

Protein C and protein S activity, Peak and ETP decrease were lower in patients with MPN than controls. Patients with Jak2V617F- had a tendency to lower sensitivity for TM in comparison with Jak2V617F+ patients. This fact could have a significant role in thrombotic complication development.

Figure

Figure

Back to Top | Article Outline

Summary/Conclusion

: Our results showed presence of activated protein C resistance probably caused by anticoagulant protein C system dysfunction. Jak2V617F influence on hemostatic parameters demands further investigations.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.